Abstract: A system and valve for regulating the level of a fluid. The valve having a floating head member that is connected via a rotatable member to a drain member, where fluid may drain from the valve. The system having the valve and a tank, where the fluid drains from the tank once the fluid level reaches the level of the drain member of the valve.

Abstract: A drainback tank having a solar return pipe, at least a portion of the solar return pipe being located within the internal body of the tank, the solar return pipe having a hole that is in close proximity to the hole of an output pipe, such that the fluid in the solar return pipe flows into the output pipe and leaves the tank housing to be used to heat the fluid of a corresponding hot water tank via convection in a heat exchanger.

Abstract: The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.

Abstract: A hot water storage tank having features to minimize heat loss and improve stratification throughout the tank. The tank having an inner lid and outer lid. The tank having a bladder. A tank having a solar stratification input pipe, the solar stratification input pipe having one or more holes, the one or more holes allowing the fluid to exit the solar stratification input pipe at a level where the fluid is of similar density to the fluid in the tank maintaining stratification throughout the tank, and the solar stratification input pipe being located within the tank and parallel to the longitudinal axis of the tank.

Abstract: A system and valve for regulating the level of a fluid. The valve having a floating head member that is connected via a rotatable member to a drain member, where fluid may drain from the valve. The system having the valve and a tank, where the fluid drains from the tank once the fluid level reaches the level of the drain member of the valve.

Abstract: The invention pertains to new aminophthalazine compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds that are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.

Abstract: A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an ?-melanocyte stimulating hormone (?-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.

Abstract: The invention pertains to substituted quinazoline compounds of structures (I) and (II) that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom. (I, II).

Abstract: This invention relates to a method of treating and preventing vascular events and circulatory disorders in a patient in need thereof, especially in a patient at risk for said indications, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions, and the use of dipyridamole for the manufacture of a corresponding pharmaceutical composition comprising a combination of dipyridamole, acetyl salicylic acid and an angiotensin II antagonist.

Abstract: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.

Abstract: A pharmaceutical composition comprising a therapeutically effective amount of: (a) dipyridamole or a pharmaceutically acceptable salt thereof, (b) acetylsalicylic acid; and (c) an angiotensin II antagonist, kits containing these three compounds, and methods for preventing stroke or reducing the risk of stroke or secondary stroke in a patient in need thereof by administering an effective amount of these compounds to the patient.

Abstract: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.

Abstract: The invention pertains to substituted quinazoline and isoquinoline compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE-10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

Abstract: A shift rail for a vehicle transmission includes multiple detent mechanisms for shifting that operate independently from each other. The shift rail includes a neutral detent mechanism that allows shifting from a neutral position into a gear engaged position at a first detent force, and an in-gear detent mechanism that allows shifting out of a gear engaged position at a second detent force that is greater than the first detent force. By setting the second detent force higher than the first detent force, un-requested shifts out of the gear engaged position, i.e. “jumpout,” can be controlled. Additionally, the neutral and in-gear detent mechanisms include separate springs where spring forces can be varied to adjust shift feel as needed.

Abstract: The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

Abstract: The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines which is capable of delivering the compound as fine, solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of these compounds in solution metered dose inhalers, which response can prevent the administration of a therapeutically effective dose and, in the long term, undermine patient compliance.

Abstract: The invention provides a therapeutic combination comprising voriconazole and an antifungal CYP2C19 inhibitor in specific quantities and weight ratios. Pharmaceutical compositions, unit dosage forms and kits comprising voriconazole and an antifungal CYP2C19 inhibitor, and their use in the treatment of fungal infections, are also provided.

Abstract: This invention relates to a new pharmaceutical formulation of voriconazole, in particular a formulation comprising one or more poloxamers.

Abstract: A process for interconverting a mixture of cis-trans isomers of a compound of formula I into the substantially pure cis isomer. Cis isomers of formula I are useful intermediates in the synthesis of cis isomers of benzamide piperidine compounds which exhibit activity as NK-1 receptor antagonists.

Abstract: The invention includes compositions and methods for detection of antibodies to the muscarinic adrenergic receptor type 3 (M3R), useful in the diagnosis of autoimmune diseases including Sjögren's sydrome.